PRMT1, a type I arginine methyltransferase, catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to an w-nitrogen of the guanidino function of protein L-arginine residues (w-monomethylation) and the transfer of a second methyl group to the same nitrogen, yielding asymmetric dimethylarginine (aDMA). A ubiquitously expressed protein and the major source of histone H4 arginine-3 methylation (H4R3me1, H4R3me2a), PRMT1 also methylates other histones and numerous other substrates, accounting for about 85% of all arginine methylation in mammalian cells. PRMT1 is essential to oncogenic transformation in mixed lineage leukemia (MLL), interacting with the MLL-EEN fusion protein in a transcription-activating complex also comprising histone acetyltransferase activity. Methylation of Arg-260 in estrogen receptor a (ERa) by PRMT1 is required for its interaction with p85 and src and ERa hypermethylation is associated with a subset of breast cancers. There is also evidence suggesting a role for elevated PRMT1 activity in heart disease and asthma. These various disease connections have made PRMT1 the target of recent HTS and drug discovery efforts.
ACCESSION #: NM_001536
INCLUDES AMINO ACIDS: 2-371 (C-term.)
TAG(S): N-terminal GST-tag
MW: 68.3 kDa
EXPRESSION SYSTEM: E. coli
SUPPLIED AS: Solution of purified recombinant protein in 25 mM Na2HPO4, 4.4 mM KH2PO4, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 3 mM DTT, 30% (w/v) glycerol.
STORAGE: -80°C, aliquot and snap-freeze after first use.
View Product Data Sheet
Substantial Discounts Available on
We also offer assay services for PRMT1.